Maravai Lifesciences lowers FY24 revenue view to $255M-$265M from $265M-$285M

Consensus $275.55M. The company said, “Maravai’s financial guidance for the full year 2024 is based on expectations for its existing business and does not include the financial impact of potential new acquisitions, including the planned acquisition of the DNA and RNA business of Officinae Bio, or items that have not yet been identified or quantified. This guidance is subject to a number of risks, uncertainties and other factors, including those identified in “Forward-looking Statements” below. Revenue expectations for 2024 are now expected to be in the range of $255.0 million to $265.0 million. Adjusted EBITDA (non-GAAP) margins are now expected to be in the range of 16% to 18%.”